Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | ELANE | P08246 | 5/20 | 0.38 |
| ▸ | MAP3K14 | Q99558 | 4/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16532529 | 0.93 | MAP3K14 (0.38) | PDE4AKCNH2ELANEMAP3K14CYP1A2 | |
| SCHEMBL16532409 | 0.88 | MAP3K14 (0.46) | PDE4AKCNH2ELANEMAP3K14CYP1A2 | |
| SCHEMBL16547225 | 0.86 | PDE4A (0.41) | PDE4AKCNH2ELANEMAP3K14KDM4E | |
| SCHEMBL16532543 | 0.85 | PDE4A (0.41) | PDE4AKCNH2ELANEMAP3K14KDM4E | |
| SCHEMBL16532478 | 0.85 | MAP3K14 (0.44) | PDE4AKCNH2ELANEMAP3K14KDM4E | |
| SCHEMBL16532672 | 0.83 | MAP3K14 (0.43) | PDE4AKCNH2ELANEMAP3K14KDM4E | |
| SCHEMBL16532372 | 0.83 | MAP3K14 (0.44) | PDE4AKCNH2ELANEMAP3K14KDM4E | |
| SCHEMBL16532532 | 0.82 | MAP3K14 (0.47) | PDE4AKCNH2ELANEMAP3K14CYP1A2 | |
| SCHEMBL16516925 | 0.82 | RARG (0.37) | PDE4AKCNH2ELANEMAP3K14SMN1; SMN2 | |
| SCHEMBL16532313 | 0.81 | PDE4A (0.48) | PDE4AKCNH2ELANEMAP3K14CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | PDE4A 1474/4885KCNH2 1777/4885ELANE 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.